ArriVent BioPharma
AVBP
106 hedge funds and large institutions have $712M invested in ArriVent BioPharma in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 19 reducing their positions, and 11 closing their positions.
142% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 19
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
7% more funds holding
Funds holding: 99 → 106 (+7)
3% less capital invested
Capital invested by funds: $732M → $712M (-$19.7M)
3.21% less ownership
Funds ownership: 98.29% → 95.07% (-3.2%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
76% less call options, than puts
Call options by funds: $424K | Put options by funds: $1.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.7M |
| 3 |
IAM
Infinitum Asset Management
Fort Lauderdale,
Florida
|
+$8.84M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.08M |
| 5 |
Morgan Stanley
New York
|
+$5.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HLAM
Hidden Lake Asset Management
New York
|
-$5.75M |
| 2 |
Squarepoint
New York
|
-$1.49M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$1.17M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$814K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$733K |
AVBP Hedge Fund Activity: Q3 2025 in Review
106 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q3 2025, worth a combined $712M — down 2.7% from $732M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AVBP positions and 11 closed out — a net gain of 7 holders — while 46 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $26.5M. The largest seller was Hidden Lake Asset Management, cutting an estimated $5.75M.
- 106 institutional investors held ArriVent BioPharma (AVBP) as of Q3 2025, up from 99 in Q2 2025.
- Funds reported $712M of ArriVent BioPharma stock for Q3 2025, down 2.7% quarter-over-quarter.
- 18 funds opened new ArriVent BioPharma positions in Q3 2025 and 11 closed out, a net change of +7 holders.
- The largest ArriVent BioPharma buyer in Q3 2025 was Fidelity Investments, an estimated $26.5M added.
- The largest ArriVent BioPharma seller in Q3 2025 was Hidden Lake Asset Management, an estimated $5.75M sold.
Based on aggregated 13F filings for Q3 2025.